Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing-remitting multiple sclerosis.
PBMCs
autoimmunity
checkpoint
co-regulation
neuroinflammation
Journal
Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
01
2023
revised:
22
06
2023
accepted:
24
07
2023
medline:
11
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
The programmed cell death protein 1/programmed cell death ligand 1 axis plays an important role in the adaptive immune system and has influence on neoplastic and inflammatory diseases, while its role in multiple sclerosis is unclear. Here, we aimed to analyse expression patterns of programmed cell death protein 1 and programmed cell death ligand 1 on peripheral blood mononuclear cells and their soluble variants in multiple sclerosis patients and controls, to determine their correlation with clinical disability and disease activity. In a cross-sectional study, we performed in-depth flow cytometric immunophenotyping of peripheral blood mononuclear cells and analysed soluble programmed cell death protein 1 and programmed cell death ligand 1 serum levels in patients with relapsing-remitting multiple sclerosis and controls. In comparison to control subjects, relapsing-remitting multiple sclerosis patients displayed distinct cellular programmed cell death protein 1/programmed cell death ligand 1 expression patterns in immune cell subsets and increased soluble programmed cell death ligand 1 levels, which correlated with clinical measures of disability and MRI activity over time. This study extends our knowledge of how programmed cell death protein 1 and programmed cell death ligand 1 are expressed in the membranes of patients with relapsing-remitting multiple sclerosis and describes for the first time the elevation of soluble programmed cell death ligand 1 in the blood of multiple sclerosis patients. The distinct expression pattern of membrane-bound programmed cell death protein 1 and programmed cell death ligand 1 and the correlation between soluble programmed cell death ligand 1, membrane-bound programmed cell death ligand 1, disease and clinical factors may offer therapeutic potential in the setting of multiple sclerosis and might improve future diagnosis and clinical decision-making.
Identifiants
pubmed: 37564830
doi: 10.1093/braincomms/fcad206
pii: fcad206
pmc: PMC10411318
doi:
Types de publication
Journal Article
Langues
eng
Pagination
fcad206Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.
Déclaration de conflit d'intérêts
The other authors report no conflicts of interest related to the contents of the manuscript.
Références
Oncoimmunology. 2020 Apr 14;9(1):1744980
pubmed: 32363112
Adv Exp Med Biol. 2020;1248:33-59
pubmed: 32185706
Nat Immunol. 2021 Oct;22(10):1190-1197
pubmed: 34489590
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Cancers (Basel). 2021 Jun 17;13(12):
pubmed: 34204509
J Immunol. 2006 Sep 15;177(6):4196-202
pubmed: 16951385
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 5;7(3):
pubmed: 32139439
Cancer Immunol Immunother. 2019 Mar;68(3):421-432
pubmed: 30564891
N Engl J Med. 2006 Feb 9;354(6):610-21
pubmed: 16467548
Crit Rev Immunol. 1998;18(5):389-418
pubmed: 9784967
Clin Exp Immunol. 2017 Jun;188(3):455-466
pubmed: 28245522
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
JAMA Neurol. 2019 May 1;76(5):536-541
pubmed: 30776055
J Immunol. 2009 Oct 15;183(8):4984-93
pubmed: 19794071
Int Immunopharmacol. 2021 Oct;99:107935
pubmed: 34304000
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Eur J Cancer. 2016 May;59:152-159
pubmed: 27039170
J Neurosci Res. 2010 Jan;88(1):7-15
pubmed: 19642196
J Immunol. 2008 Nov 15;181(10):6738-46
pubmed: 18981091
Semin Immunopathol. 2015 Nov;37(6):625-38
pubmed: 26223505
Front Immunol. 2018 Sep 27;9:2129
pubmed: 30356906
Neurotherapeutics. 2022 Apr;19(3):774-784
pubmed: 35289375
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
J Dermatol. 2016 Aug;43(8):954-7
pubmed: 26945563
Autoimmunity. 2016 Jun;49(4):219-28
pubmed: 26829210
Front Immunol. 2020 Dec 18;11:606338
pubmed: 33391273
Oncoimmunology. 2017 Mar 31;6(5):e1310358
pubmed: 28638732
Immunol Rev. 2012 Jul;248(1):122-39
pubmed: 22725958
Nat Protoc. 2021 Aug;16(8):3775-3801
pubmed: 34172973
Eur J Immunol. 2010 Jan;40(1):254-66
pubmed: 19830728
Oncoimmunology. 2015 Oct 29;5(3):e1091146
pubmed: 27141350
Am J Pathol. 2009 Jun;174(6):2290-9
pubmed: 19443704
J Immunol. 2006 Dec 15;177(12):8844-50
pubmed: 17142787
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
Elife. 2019 Nov 15;8:
pubmed: 31729316
Mayo Clin Proc. 2014 Feb;89(2):225-40
pubmed: 24485135
Front Cell Infect Microbiol. 2019 Jun 13;9:207
pubmed: 31263684
Eur J Immunol. 2010 Dec;40(12):3347-57
pubmed: 21110318
Lancet Neurol. 2015 Apr;14(4):406-19
pubmed: 25792099
Auto Immun Highlights. 2010 Nov 04;1(2):73-81
pubmed: 26000110
Scand J Immunol. 2020 Jul;92(1):e12884
pubmed: 32243638
Nat Rev Immunol. 2012 Feb 17;12(3):191-200
pubmed: 22343568
JAMA. 2019 Jan 15;321(2):175-187
pubmed: 30644981
Scand J Gastroenterol. 2017 Jan;52(1):93-99
pubmed: 27604386
Annu Rev Pathol. 2022 Jan 24;17:121-139
pubmed: 34606377
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Neurol Neuroimmunol Neuroinflamm. 2020 Dec 24;8(2):
pubmed: 33361385
Neurol Neuroimmunol Neuroinflamm. 2022 Apr 5;9(4):
pubmed: 35383094
Front Immunol. 2014 Sep 24;5:457
pubmed: 25309541
J Neuroimmunol. 2017 Apr 15;305:115-127
pubmed: 28284331
Sci Rep. 2019 Dec 19;9(1):19471
pubmed: 31857644
Front Neurol. 2020 Dec 11;11:538695
pubmed: 33362680